Andrew Sauer, MD
Advanced Heart Failure and Transplant Cardiology · Lees Summit, MONPI 1356546956
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $255,762 of the $411,083 with a category attached, or 62.2%. 20 manufacturers reported payments, led by Abbott at 51.2% of the total. 2025 is the largest year on record at $87,904, 2.1 times the $41,507 reported in 2019. Among advanced heart failure and transplant cardiology clinicians in MO with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 450 payments — averaging $913.52 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Abbott$210K
- Impulse Dynamics (USA) Inc.$55K
- Boston Scientific$51K
- Bayer$36K
- Amgen$15K
- Novartis$14K
- plus $29K from 14 others
Across 330 payments — averaging $9878.99 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Abbott$1M
- Bayer$784K
- Edwards Lifesciences$750K
- Amgen$162K
- Vifor (international) Ltd.$156K
- Novartis$146K
- plus $246K from 8 others
What the payments were for
- Consulting fees$255,76262%
- Speaking & faculty fees$122,18230%
- Travel & lodging$19,7425%
- Food & beverage$13,3243%
- Education$730%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Abbott | 232 | $210,456 |
| Impulse Dynamics (USA) Inc. | 43 | $55,309 |
| Boston Scientific | 63 | $50,883 |
| Bayer | 28 | $35,687 |
| Amgen | 12 | $15,362 |
| Novartis | 19 | $14,388 |
| Medtronic(2 entities) | 16 | $12,462 |
| Edwards Lifesciences | 13 | $6,747 |
| Roche Diagnostics Corporation | 1 | $2,980 |
| Terumo Medical Corporation | 6 | $2,800 |
| Boehringer Ingelheim | 1 | $2,715 |
| Impedimed, Inc. | 1 | $500 |
| Endotronix, Inc. | 2 | $379 |
| Cvrx, Inc. | 3 | $225 |
| Idorsia Pharmaceuticals US Inc | 1 | $60 |
| AstraZeneca | 2 | $42 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 3 | $34 |
| Pfizer | 2 | $29 |
| Sanofi-aventis U.S. LLC | 1 | $13 |
| Kowa Pharmaceuticals America, Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- OPTIMIZER$82,839
- MitraClip$69,500
- CARDIOMEMS$42,181
- MitraClip System$39,875
- Kerendia$35,225
- GENERAL - THERAPIES$33,560
- ENTRESTO$14,246
- CardioMEMS HF System$13,561
- 2ND GEN CENTRIMAG PRIMARY CONSOLE$13,000
- HeartWare HVAD$11,946
- THORATEC HEARTMATE 3 LVAS IMPLANT KIT$11,788
- OPTIMIZER SMART SYSTEM$10,374
- Mitra Clip system$8,125
- SJM REGENT$5,000
- CLINICAL TRIAL PRODUCT$4,288
- JARDIANCE$2,715
- LATITUDE$2,500
- HeartMate 3 Left Ventricular Assist Device$2,427
- HeartMate$1,274
- GENERAL - STRUCTURAL HEART$1,250
How this compares
$411,083 in reported general payments places this provider in the 95th percentile of 26 advanced heart failure and transplant cardiology providers in Missouri.
See all advanced heart failure and transplant cardiology providers in Missouri →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 177 | $165,812 |
| EntrestoSacubitril/Valsartan | 142 | $147,119 |
| OzempicSemaglutide | 105 | $120,071 |
| EliquisApixaban | 109 | $93,580 |
| MounjaroTirzepatide | 24 | $25,240 |
| XareltoRivaroxaban | 21 | $18,378 |
| Repatha SureclickEvolocumab | 13 | $14,880 |
| Sirolimus | 12 | $6,618 |
| Eplerenone | 96 | $6,371 |
| Tacrolimus | 47 | $3,606 |
| Mycophenolate Mofetil | 26 | $1,961 |
| Metoprolol Succinate | 182 | $1,794 |
| Rosuvastatin Calcium | 116 | $1,609 |
| Spironolactone | 253 | $1,559 |
| Torsemide | 63 | $1,478 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimJardiance | $2,715 | $165,812177 claims |
| NovartisEntresto | $14,388 | $147,119142 claims |
| PfizerEliquis | $29 | $93,580109 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 26 advanced heart failure and transplant cardiology providers in Missouri.
Other advanced heart failure and transplant cardiology in Lees Summit
- Timothy FendlerLees Summit$15K
- Ahmad TurkLees Summit$502
- Gerard OghlakianSpringfield$365K
- Brett SperryKansas City$314K
- Shane LarueHannibal$41K
- Gregory EwaldSaint Louis$35K
- Sumanth PrabhuSaint Louis$35K
- Nancy SweitzerSaint Louis$32K
- Michael NassifKansas City$32K
- Justin HartupeeSaint Louis$30K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.